January 2020 – Aggressive NHL is among the most common cancers in SSA where CHOP is the standard treatment and outcomes are poor. We treated patients with a modified EPOCH regimen with moderate outcomes. Results indicate that this regimen was feasible and effective in a small cohort and suggest EPOCH with setting-appropriate modifications may be … Continued
Category: Scientific Outputs
October 2019 – Increasing access to conventional cancer treatment in low-income countries is an important public health initiative to address the global burden of cancer. Our findings indicate that cancer patients in our cohort rely on a pragmatic and experience-based treatment selection process and provide insights to the various factors that influence T&CM use among cancer … Continued
July 2019 – Cost analysis of treating diffuse large B-cell lymphoma (DLBCL) in Malawi indicates that per-patient cost of first-line treatment of DLBCL in Malawi is low relative to high-income countries, suggesting that investments in fixed-duration, curative-intent DLBCL treatment may be attractive in sub-Saharan Africa.
April 2019 – Studies on malignant melanoma have largely focused on Caucasian populations with very limited data on the disease in black Africans. This retrospective study characterizes melanoma cases in Lilongwe, Malawi and demonstrates that malignant melanoma occurs in black Malawians and may be an under-appreciated malignancy.
February 2019 – Although Burkitt lymphoma (BL) is common in sub-Saharan Africa (SSA) and highly curable in high-income countries, there are few prospective nonpediatric BL studies from SSA and no regional standard of care. This study represents one of the best characterized prospective cohorts of nonpediatric BL in SSA.
December 2018- In sub-Saharan Africa, limited epidemiological data describe cancer burden among ART users. We link cases from the population-based cancer registry with EMRs supporting ART delivery in Malawi’s two largest HIV cohorts, Lighthouse Trust and Queen Elizabeth Central Hospital to identify cancer burden.